@DanielleHammo20 This is in continuation of our work in Blood Cancer Discovery https://t.co/WRLM7aO05T

We still hot in market for therapeutic strategy https://t.co/Km4nf8ZgFx

RT @_TanyaBondar_: The first session of #AACRCH21 is about DTA (Dnmt3, Tet, Asxl) mutations. Read this @BCD_AACR article presenting a new s…

RT @_TanyaBondar_: The first session of #AACRCH21 is about DTA (Dnmt3, Tet, Asxl) mutations. Read this @BCD_AACR article presenting a new s…

RT @_TanyaBondar_: The first session of #AACRCH21 is about DTA (Dnmt3, Tet, Asxl) mutations. Read this @BCD_AACR article presenting a new s…

The first session of #AACRCH21 is about DTA (Dnmt3, Tet, Asxl) mutations. Read this @BCD_AACR article presenting a new strategy targeting clonal Tet2 mutations: https://t.co/V9TVsq0PsR

RT @Neoplasm16: A Therapeutic Strategy for Preferential Targeting of TET2-Mutant and TET Dioxygenase–Deficient Cells in Myeloid Neoplasms h…

A Therapeutic Strategy for Preferential Targeting of TET2-Mutant and TET Dioxygenase–Deficient Cells in Myeloid Neoplasms https://t.co/inlxhGnsiv

Small molecules magic

#ICYMI: A Therapeutic Strategy for Preferential Targeting of TET2-Mutant and TET Dioxygenase–Deficient Cells in Myeloid Neoplasms. @yihong_guan @ClevelandClinic @leukaemielabor https://t.co/2opneZyCu1 https://t.co/SbkyTxH4sP

Chemistry and biology interface and therapeutic approach

ICYMI: A Therapeutic Strategy for Preferential Targeting of TET2-Mutant and TET Dioxygenase–Deficient Cells in Myeloid Neoplasms. @yihong_guan @ClevelandClinic @leukaemielabor https://t.co/iPbQfQ4k4D https://t.co/IY8ZEouMwK

TETmt vs TETi76, please join us to enjoy the game

March 15: @AACR Virtual Journal Club Jaroslaw Maciejewski and @babal_jha discuss their paper, "Minimal TET activity is targetable vulnerability of Tet2 and neomorphic IDH1/2-mutant myeloid malignancies." Read the paper: https://t.co/Ngi1t7evjO Register: h

@medchem magic 🪄 if you understood it’s science don’t it’s magic

From the March issue: A Therapeutic Strategy for Preferential Targeting of TET2-Mutant and TET Dioxygenase–Deficient Cells in Myeloid Neoplasms. @yihong_guan @ClevelandClinic @leukaemielabor https://t.co/FuwXTq237d https://t.co/aQ2oAnqINj

RT @BCD_AACR: March 15: @AACR Virtual Journal Club Jaroslaw Maciejewski and @babal_jha discuss their paper, "Minimal TET activity is targe…

March 15: @AACR Virtual Journal Club Jaroslaw Maciejewski and @babal_jha discuss their paper, "Minimal TET activity is targetable vulnerability of Tet2 and neomorphic IDH1/2-mutant myeloid malignancies." Read the paper: https://t.co/zNMRFN9zfc Register: h

New article: A Therapeutic Strategy for Preferential Targeting of TET2 Mutant and TET-dioxygenase Deficient Cells in Myeloid Neoplasms https://t.co/gj0RRBpuSN #MDS #mdssm #hematology https://t.co/GROS3OUKPa

Our work published are going to discuss by leaders

RT @BCD_AACR: March 15: @AACR Virtual Journal Club Jaroslaw Maciejewski and @babal_jha discuss their paper, "Minimal TET activity is targe…

March 15: @AACR Virtual Journal Club Jaroslaw Maciejewski and @babal_jha discuss their paper, "Minimal TET activity is targetable vulnerability of Tet2 and neomorphic IDH1/2-mutant myeloid malignancies." https://t.co/tG1pN4HSYP Register: https://t.co/QI

RT @BCD_AACR: March 15: @AACR Virtual Journal Club Jaroslaw Maciejewski and @babal_jha discuss their paper, "Minimal TET activity is targe…

RT @BCD_AACR: March 15: @AACR Virtual Journal Club Jaroslaw Maciejewski and @babal_jha discuss their paper, "Minimal TET activity is targe…

RT @BCD_AACR: March 15: @AACR Virtual Journal Club Jaroslaw Maciejewski and @babal_jha discuss their paper, "Minimal TET activity is targe…

RT @BCD_AACR: March 15: @AACR Virtual Journal Club Jaroslaw Maciejewski and @babal_jha discuss their paper, "Minimal TET activity is targe…

RT @_TanyaBondar_: Why TET and IDO mutations are synthetic lethal? How to exploit this vulnerability for therapy of myeloid neoplasias? Lea…

RT @BCD_AACR: March 15: @AACR Virtual Journal Club Jaroslaw Maciejewski and @babal_jha discuss their paper, "Minimal TET activity is targe…

RT @BCD_AACR: March 15: @AACR Virtual Journal Club Jaroslaw Maciejewski and @babal_jha discuss their paper, "Minimal TET activity is targe…

RT @_TanyaBondar_: Why TET and IDO mutations are synthetic lethal? How to exploit this vulnerability for therapy of myeloid neoplasias? Lea…

Why TET and IDO mutations are synthetic lethal? How to exploit this vulnerability for therapy of myeloid neoplasias? Learn about conceptual and translational advances at the next @BCD_AAR journal club on March 15th. Read the paper, send me Q for the speak

RT @BCD_AACR: March 15: @AACR Virtual Journal Club Jaroslaw Maciejewski and @babal_jha discuss their paper, "Minimal TET activity is targe…

March 15: @AACR Virtual Journal Club Jaroslaw Maciejewski and @babal_jha discuss their paper, "Minimal TET activity is targetable vulnerability of Tet2 and neomorphic IDH1/2-mutant myeloid malignancies." Register: https://t.co/ciaGbj9Ahs Read the paper: h

RT @BCD_AACR: Just published #OnlineFirst: A Therapeutic Strategy for Preferential Targeting of TET2-Mutant and TET Dioxygenase–Deficient C…

RT @BCD_AACR: Just published #OnlineFirst: A Therapeutic Strategy for Preferential Targeting of TET2-Mutant and TET Dioxygenase–Deficient C…

RT @BCD_AACR: Just published #OnlineFirst: A Therapeutic Strategy for Preferential Targeting of TET2-Mutant and TET Dioxygenase–Deficient C…

RT @AnandDevTiwari1: We are on the cover page thanks to @yihong_guan, @babal_jha, Dr. Maciejewaski, Dr. Phillips. 4 years work with team sp…

RT @BCD_AACR: Just published #OnlineFirst: A Therapeutic Strategy for Preferential Targeting of TET2-Mutant and TET Dioxygenase–Deficient C…

RT @AnandDevTiwari1: We are on the cover page thanks to @yihong_guan, @babal_jha, Dr. Maciejewaski, Dr. Phillips. 4 years work with team sp…

RT @BCD_AACR: Just published #OnlineFirst: A Therapeutic Strategy for Preferential Targeting of TET2-Mutant and TET Dioxygenase–Deficient C…

RT @BCD_AACR: Just published #OnlineFirst: A Therapeutic Strategy for Preferential Targeting of TET2-Mutant and TET Dioxygenase–Deficient C…

RT @AnandDevTiwari1: We are on the cover page thanks to @yihong_guan, @babal_jha, Dr. Maciejewaski, Dr. Phillips. 4 years work with team sp…

We are on the cover page thanks to @yihong_guan, @babal_jha, Dr. Maciejewaski, Dr. Phillips. 4 years work with team sprites come out like this @ClevelandClinic @CCLRI

RT @BCD_AACR: Just published #OnlineFirst: A Therapeutic Strategy for Preferential Targeting of TET2-Mutant and TET Dioxygenase–Deficient C…

RT @BCD_AACR: Just published #OnlineFirst: A Therapeutic Strategy for Preferential Targeting of TET2-Mutant and TET Dioxygenase–Deficient C…

Just published #OnlineFirst: A Therapeutic Strategy for Preferential Targeting of TET2-Mutant and TET Dioxygenase–Deficient Cells in Myeloid Neoplasms. @yihong_guan @ClevelandClinic @leukaemielabor https://t.co/k6fNB0yyGo https://t.co/zdhr8JaNyw

RT @yihong_guan: A four-year work through the collaboration with chemists, biologist and physician scientist. A Therapeutic Strategy for…

RT @yihong_guan: A four-year work through the collaboration with chemists, biologist and physician scientist. A Therapeutic Strategy for…

RT @TheDoctorIsVin: A clear mechanism for the observed mutual exclusivity of IDH & TET2 mutations, and a SL therapy in TET2 mutant context…

RT @TheDoctorIsVin: A clear mechanism for the observed mutual exclusivity of IDH & TET2 mutations, and a SL therapy in TET2 mutant context…

RT @_TanyaBondar_: @DanielleHammo20 Related to TET2 LOF targeting: 2HG mimetic TETi76 selectively inhibits growth of Tet2 and IDH mutant…

RT @babal_jha: A Therapeutic Strategy for Preferential Targeting of TET2 Mutant and TET-dioxygenase Deficient Cells in Myeloid Neoplasms ht…

RT @babal_jha: A Therapeutic Strategy for Preferential Targeting of TET2 Mutant and TET-dioxygenase Deficient Cells in Myeloid Neoplasms ht…

RT @babal_jha: A Therapeutic Strategy for Preferential Targeting of TET2 Mutant and TET-dioxygenase Deficient Cells in Myeloid Neoplasms ht…

RT @LurieCancer: Results published in @BCD_AACR suggest TET inhibitors may constitute a new class of targeted agents in TET2 mutant neoplas…

RT @BCD_AACR: ICYMI: A Therapeutic Strategy for Preferential Targeting of TET2 Mutant and TET-dioxygenase Deficient Cells in #Myeloid Neopl…

RT @LurieCancer: Results published in @BCD_AACR suggest TET inhibitors may constitute a new class of targeted agents in TET2 mutant neoplas…

RT @babal_jha: A Therapeutic Strategy for Preferential Targeting of TET2 Mutant and TET-dioxygenase Deficient Cells in Myeloid Neoplasms ht…

A Therapeutic Strategy for Preferential Targeting of TET2 Mutant and TET-dioxygenase Deficient Cells in Myeloid Neoplasms https://t.co/QfpckXo9wW

RT @TheDoctorIsVin: A clear mechanism for the observed mutual exclusivity of IDH & TET2 mutations, and a SL therapy in TET2 mutant context…

Terrific work by colleagues at @ClevelandClinic Jarek and Jha - congratulations! https://t.co/3DgpgUfdou

https://t.co/PNsdWQqi5D Therapy for TET2 deficiency

RT @LurieCancer: Results published in @BCD_AACR suggest TET inhibitors may constitute a new class of targeted agents in TET2 mutant neoplas…

RT @sethcorey: https://t.co/dkxzR8fMB0 A Tet offensive

RT @JustinLathia: Congrats to Drs. Babal Jha and Jarek Maciejewski on these exciting new findings published in @BCD_AACR : https://t.co/K4M…

A Therapeutic Strategy for Preferential Targeting of TET2 Mutant and TET-dioxygenase Deficient Cells in Myeloid Neoplasms https://t.co/e3eY4uXJ5c #animalresearch #mice https://t.co/mH98gTjCpx

RT @JustinLathia: Congrats to Drs. Babal Jha and Jarek Maciejewski on these exciting new findings published in @BCD_AACR : https://t.co/K4M…

RT @JustinLathia: Congrats to Drs. Babal Jha and Jarek Maciejewski on these exciting new findings published in @BCD_AACR : https://t.co/K4M…

RT @JustinLathia: Congrats to Drs. Babal Jha and Jarek Maciejewski on these exciting new findings published in @BCD_AACR : https://t.co/K4M…

RT @JustinLathia: Congrats to Drs. Babal Jha and Jarek Maciejewski on these exciting new findings published in @BCD_AACR : https://t.co/K4M…

RT @JustinLathia: Congrats to Drs. Babal Jha and Jarek Maciejewski on these exciting new findings published in @BCD_AACR : https://t.co/K4M…

Congrats to Drs. Babal Jha and Jarek Maciejewski on these exciting new findings published in @BCD_AACR : https://t.co/K4Mv6kcm2d Another great translational study from @CCLRI @caseccc @ClevelandClinic - great teamwork as well from @DrOmarMian @MikkaelSeker

https://t.co/dkxzR8fMB0 A Tet offensive

RT @LurieCancer: Results published in @BCD_AACR suggest TET inhibitors may constitute a new class of targeted agents in TET2 mutant neoplas…

RT @BCD_AACR: ICYMI: A Therapeutic Strategy for Preferential Targeting of TET2 Mutant and TET-dioxygenase Deficient Cells in #Myeloid Neopl…

RT @LurieCancer: Results published in @BCD_AACR suggest TET inhibitors may constitute a new class of targeted agents in TET2 mutant neoplas…

RT @LurieCancer: Results published in @BCD_AACR suggest TET inhibitors may constitute a new class of targeted agents in TET2 mutant neoplas…

Results published in @BCD_AACR suggest TET inhibitors may constitute a new class of targeted agents in TET2 mutant neoplasia. @theabzlab #AML #MDS #leukemia #leusm

ICYMI: A Therapeutic Strategy for Preferential Targeting of TET2 Mutant and TET-dioxygenase Deficient Cells in #Myeloid Neoplasms. @CCLRI @ClevelandClinic @leukaemielabor @LurieCancer @SylvesterCancer #MPN https://t.co/TLEevIHFLO https://t.co/fM2gFfgx8m

TET mutant target therapeutic approach

RT @SylvesterCancer: Results of treatment with TET inhibitor. @MikkaelSekeres is a co-author of this research article.

RT @SylvesterCancer: Results of treatment with TET inhibitor. @MikkaelSekeres is a co-author of this research article.

RT @BCD_AACR: Just published #OnlineFirst: A Therapeutic Strategy for Preferential Targeting of TET2 Mutant and TET-dioxygenase Deficient…

Results of treatment with TET inhibitor. @MikkaelSekeres is a co-author of this research article.

RT @BCD_AACR: Just published #OnlineFirst: A Therapeutic Strategy for Preferential Targeting of TET2 Mutant and TET-dioxygenase Deficient…

RT @BCD_AACR: Just published #OnlineFirst: A Therapeutic Strategy for Preferential Targeting of TET2 Mutant and TET-dioxygenase Deficient…

RT @BCD_AACR: Just published #OnlineFirst: A Therapeutic Strategy for Preferential Targeting of TET2 Mutant and TET-dioxygenase Deficient…

RT @_TanyaBondar_: #ASH20 TET2mut is mutually exclusive with IDH1/2 in #AML, #MDS, suggesting 2HG additive accumulation is toxic in TET, ID…

RT @BldCancerDoc: #CleClinicCancer Jha/Maciejewski lab paper that lays foundation for TET-specific inhibitors as potential Rx for TET2+ mye…

RT @BldCancerDoc: #CleClinicCancer Jha/Maciejewski lab paper that lays foundation for TET-specific inhibitors as potential Rx for TET2+ mye…

#CleClinicCancer Jha/Maciejewski lab paper that lays foundation for TET-specific inhibitors as potential Rx for TET2+ myeloid neoplasia @BCD_AACR #leusm #mdssm https://t.co/Jk0aqE8Yv5

Synthetic lethality TET2 mutant #Chemistry

Synthetic chemistry approach for targeting TET2 mutants

RT @_TanyaBondar_: #ASH20 TET2mut is mutually exclusive with IDH1/2 in #AML, #MDS, suggesting 2HG additive accumulation is toxic in TET, ID…

A Therapeutic Strategy for Preferential Targeting of TET2 Mutant and TET-dioxygenase Deficient Cells in Myeloid Neoplasms https://t.co/v0Lnm4zRQR

RT @_TanyaBondar_: #ASH20 TET2mut is mutually exclusive with IDH1/2 in #AML, #MDS, suggesting 2HG additive accumulation is toxic in TET, ID…

Targeting TET2 mutation with small molecule approach #CCF #Taussing CancerCentre. I m the #Chemist in this article.

@DanielleHammo20 Related to TET2 LOF targeting: 2HG mimetic TETi76 selectively inhibits growth of Tet2 and IDH mutant #AML. Read this work @BCD_AACR: https://t.co/WKn0WYmoIm @yihong_guan @CCLRI @ClevelandClinic @leukaemielabor @LurieCancer @SylvesterCan

#ASH20 TET2mut is mutually exclusive with IDH1/2 in #AML, #MDS, suggesting 2HG additive accumulation is toxic in TET, IDH-mut cells. 2HG mimetic TETi76 selectively inhibits Tet2 and IDH1/2 mutant #AML. Read this @BCD_AACR: https://t.co/WKn0WYmoIm @yihong

RT @BCD_AACR: Just published #OnlineFirst: A Therapeutic Strategy for Preferential Targeting of TET2 Mutant and TET-dioxygenase Deficient…